Urbanski Paul P, Nasra Wasim, Heinz Nicolas, Irimie Vadim, Thamm Tarvo, Ahmidou Akram, Diegeler Anno, Lenos Aristidis
Department of Cardiovascular Surgery, Cardiovascular Clinic Campus Bad Neustadt, Bad Neustadt, Germany.
Department for Medical Statistics, Campus Bad Neustadt, Bad Neustadt, Germany.
Ann Thorac Surg Short Rep. 2023 Nov 28;2(1):6-10. doi: 10.1016/j.atssr.2023.11.012. eCollection 2024 Mar.
The aim of the study was to evaluate the long-term results after aortic root replacement using a self-assembled composite graft with a biological valve prosthesis.
Between 1998 and 2021, a total of 308 bio-Bentall procedures were performed by use of the described technique exclusively. The average age of the cohort patients was 68.5 ± 9.0 years; 77 patients were younger than 65 years (mean, 55.9 ± 7.4 years). The indication for root replacement was chronic aneurysm in 215 patients (69.8%).
Early (30-day/in-hospital) mortality was 4.9% for the entire cohort and 0% for the patients with chronic root aneurysm. The survival at 15 years was 41.9% ± 4.1% for all patients and 62.5% ± 9.3% for those younger than 65 years. Multivariate statistical analysis revealed patient's age, New York Heart Association class IV, no sinus rhythm, and postoperative dialysis as independent risk factors for late mortality. The cumulative risk of aortic valve reintervention due to prosthesis degeneration at 15 years was 7.7% ± 2.45%. During the mean follow-up of 96 months (range, 0-279 months), there were 19 reinterventions on the aortic valve or root altogether. In patients with acute endocarditis (7), a complete root re-replacement was necessary, yet in all 12 patients with valve degeneration, the reintervention (open re-replacement in 10, valve-in-valve in 2) could be limited to the aortic valve prosthesis, leaving the aortic tube and coronary ostia untouched.
Aortic root replacement by the described self-assembled biological valve composite graft enables a safe replacement of the degenerated valve prosthesis within the conduit and can therefore be recommended in younger patients.
本研究的目的是评估使用带有生物瓣膜假体的自组装复合移植物进行主动脉根部置换后的长期结果。
1998年至2021年期间,仅使用所述技术共进行了308例生物Bentall手术。队列患者的平均年龄为68.5±9.0岁;77例患者年龄小于65岁(平均55.9±7.4岁)。根部置换的指征为215例患者(69.8%)患有慢性动脉瘤。
整个队列的早期(30天/住院期间)死亡率为4.9%,慢性根部动脉瘤患者的死亡率为0%。所有患者15年生存率为41.9%±4.1%,65岁以下患者为62.5%±9.3%。多变量统计分析显示患者年龄、纽约心脏协会IV级、无窦性心律和术后透析是晚期死亡的独立危险因素。15年时因假体退变导致主动脉瓣再次干预的累积风险为7.7%±2.45%。在平均96个月(范围0 - 279个月)的随访期间,主动脉瓣或根部总共进行了19次再次干预。对于急性心内膜炎患者(7例),需要进行完整的根部再次置换,但在所有12例瓣膜退变患者中,再次干预(10例为开放式再次置换,2例为瓣中瓣)可仅限于主动脉瓣假体,而不触及主动脉管和冠状动脉开口。
使用所述自组装生物瓣膜复合移植物进行主动脉根部置换能够安全地置换管道内退变的瓣膜假体,因此可推荐用于年轻患者。